z-logo
open-access-imgOpen Access
Abacavir–Lamivudine versus Tenofovir–Emtricitabine for Initial HIV-1 Therapy
Author(s) -
Paul E. Sax,
Camlin Tierney,
Ann C. Collier,
Margaret A. Fischl,
Katie R. Mollan,
Lynne Peeples,
Catherine Godfrey,
Nasreen C. Jahed,
Laurie Myers,
David Katzenstein,
Awny Farajallah,
James F. Rooney,
Belinda Ha,
William C. Woodward,
Susan L. Koletar,
Victoria A. Johnson,
P. Jan Geiseler,
Eric S. Daar
Publication year - 2009
Publication title -
new england journal of medicine
Language(s) - Uncategorized
Resource type - Journals
SCImago Journal Rank - 19.889
H-Index - 1030
eISSN - 1533-4406
pISSN - 0028-4793
DOI - 10.1056/nejmoa0906768
Subject(s) - abacavir , emtricitabine , lamivudine , medicine , efavirenz , ritonavir , lopinavir , virology , reverse transcriptase inhibitor , atazanavir , viral load , gastroenterology , human immunodeficiency virus (hiv) , virus , antiretroviral therapy , hepatitis b virus
The use of fixed-dose combination nucleoside reverse-transcriptase inhibitors (NRTIs) with a nonnucleoside reverse-transcriptase inhibitor or a ritonavir-boosted protease inhibitor is recommended as initial therapy in patients with human immunodeficiency virus type 1 (HIV-1) infection, but which NRTI combination has greater efficacy and safety is not known.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom